At a glance
- Originator Cephalon
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 19 Jun 2005 Phase-II clinical trials in Solid tumours in USA (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 04 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the pharmacokinetics section